Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial (NCT05961839), SGR-2921 had originally shown activity as a monotherapy; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results